One Wealth Management Investment & Advisory Services LLC Purchases Shares of 8,434 Abbott Laboratories (NYSE:ABT)

One Wealth Management Investment & Advisory Services LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,434 shares of the healthcare product maker’s stock, valued at approximately $928,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Morgan Stanley raised its position in Abbott Laboratories by 14.3% during the 4th quarter. Morgan Stanley now owns 38,966,499 shares of the healthcare product maker’s stock valued at $4,278,132,000 after purchasing an additional 4,886,954 shares during the last quarter. Wellington Management Group LLP raised its position in Abbott Laboratories by 4.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock valued at $3,022,564,000 after purchasing an additional 1,298,219 shares during the last quarter. Moneta Group Investment Advisors LLC raised its position in Abbott Laboratories by 104,649.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 30,247,436 shares of the healthcare product maker’s stock valued at $3,320,866,000 after purchasing an additional 30,218,560 shares during the last quarter. Northern Trust Corp raised its position in Abbott Laboratories by 1.5% during the 3rd quarter. Northern Trust Corp now owns 23,016,235 shares of the healthcare product maker’s stock valued at $2,229,122,000 after purchasing an additional 343,559 shares during the last quarter. Finally, Norges Bank bought a new position in Abbott Laboratories during the 4th quarter valued at approximately $1,893,715,000. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Raymond James increased their target price on Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $128.00 target price on shares of Abbott Laboratories in a research report on Wednesday, February 14th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Barclays increased their target price on Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Finally, Wells Fargo & Company increased their target price on Abbott Laboratories from $116.00 to $121.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 13th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.14.

Abbott Laboratories Stock Up 1.0 %

ABT traded up $1.09 during trading on Friday, hitting $111.20. 5,589,244 shares of the company’s stock traded hands, compared to its average volume of 6,538,500. The company’s 50 day simple moving average is $114.96 and its two-hundred day simple moving average is $106.91. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The stock has a market capitalization of $192.95 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 2.68 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 EPS for the quarter, meeting the consensus estimate of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The business had revenue of $10.24 billion for the quarter, compared to the consensus estimate of $10.19 billion. During the same period last year, the business posted $1.03 EPS. The company’s revenue was up 1.5% compared to the same quarter last year. Analysts predict that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a yield of 1.98%. Abbott Laboratories’s dividend payout ratio is 67.48%.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the transaction, the executive vice president now directly owns 65,027 shares in the company, valued at approximately $7,315,537.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $14,895,094.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the transaction, the executive vice president now owns 65,027 shares in the company, valued at $7,315,537.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,435 shares of company stock worth $6,451,298. Insiders own 1.10% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.